Pharmaceutical companies Xcell Biosciences (Xcellbio) and aCGT Vector have partnered to expedite the development of cell and gene therapies.
The two companies will aim to improve the manufacturing and analytic procedures used to develop personalised cell and gene therapies to treat cancer patients.
aCGT Vector will offer its point-of-care, GMP-licensed manufacturing platform for validating Xcellbio’s core next-generation manufacturing and analytical AVATAR AI technology for use in treating precision cancer.
In addition, aCGT Vector’s GMP-compliant manufacturing environment will demonstrate the use of the AVATAR AI technology in developing and deploying the cell therapeutic procedures that are proximal to cancer patients’ treatment.
The AVATAR AI technology will mimic the tumour microenvironment ex vivo and provide capabilities that support the therapeutic products’ development with improved potency and persistence, as well as reduced cell exhaustion.
Xcellbio co-founder and CEO Brian Feth said: “We are pleased to partner with aCGT Vector and to pair their manufacturing expertise with our unique approach to measuring and improving therapeutic potency.
“Together, our objective is to advance the development and deployment of cell therapies, such as CAR-T and tumour-infiltrating lymphocyte technologies, to treat solid tumours.
“We look forward to supporting aCGT and their initiatives, including the next-generation cell therapies for the cancer-focused HEALED Consortium.”
Xcellbio said that the AVATAR AI technology uses the tight environmental control of the AVATAR product family.
The technology is currently in late-stage beta and focused on establishing next-generation immunotherapy testing workflows.
aCGT Vector CEO and co-founder Gary McAuslan said: “We are looking forward to working with the Xcellbio team and to utilizing the well-established AVATAR platform to further power our TaaS platform to deliver and deploy precision medicine proximal to patients.
“We believe our joint efforts will further accelerate the creation of automated, end-to-end cell therapy manufacturing and QC release platforms to streamline processing and optimise patient outcomes.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
